Lab Industry Buzz: The 10 Biggest DX Mergers of 2019

Publication Date: Feb 1, 2020

Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. (See DX Deals on page 1 for the details.) Here are the 10-highest value M&A diagnostics deals that did come off in 2019.

Top 10 Lab M&A Deals of 2019

Rank	Buyer	Target	Reported Price
1	Danaher	GE Biopharma	$21.4 billion
2	Exact Sciences	Genomic Health	$2.8 billion (cash + stock)
3	Thermo Fisher Scientific	Brammer Bio	$1.7 billion
4	Agilent Technologies	BioTek Instruments	$1.17 billion
5	PHC Holdings (formerly known as Panasonic Healthcare Holdings)	Thermo Fisher Scientific	$1.14 billion
6	Sartorius	Danaher	$750 million*
7	Covance Drug Development (part of LabCorp)	Envigo	$485 million
8	Beckman Coulter Life Sciences	Labcyte	$308 million
9	PerkinElmer	Cisbio Bioassays	$219.8 million
10	Clayton, Dubilier & Rice investment funds	Cynosure (owned by Hologic)	$205 million

* Announced in 2019 with closing scheduled for 2020

**************

This article originally appeared in G2 Intelligence, Laboratory Industry Report, January 2020

First Name		*
Last Name		*
Email		*
Customer ID